Skin neoplasm

Summary

Skin neoplasm (MONDO:0002531) is a cancer (an umbrella term covering 17 Mondo subtypes) with 1 cohort gene (234 GWAS associations across 46 studies; 1 CIViC-evidence somatic driver; 1 ClinVar predisposition record) and 87 clinical trials. Top therapeutic interventions include aminolevulinic acid, sonidegib, and axitinib.

At a glance

• Classification: Cancer
• Umbrella term: 17 Mondo subtypes
• Cohort genes: 1
• GWAS associations: 234
• ClinVar variants: 1
• Clinical trials: 87

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin neoplasm
Mondo ID	MONDO:0002531
EFO	EFO:0004198
MeSH	D012878
DOID	DOID:3165
NCIT	C3372
SNOMED CT	126488004
UMLS	C0037286
MedGen	19993
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	yes

Also known as: neoplasm of skin · neoplasm of the skin · neoplasm of zone of skin · skin · skin neoplasm · skin neoplasms · skin tumor · skin tumour · tumor of skin · tumor of the skin · tumor of zone of skin · tumour of skin · tumour of the skin · tumour of zone of skin · zone of skin neoplasm · zone of skin neoplasm (disease) · zone of skin tumor · zone of skin tumour

Data availability: 1 ClinVar variant · 234 GWAS associations (46 studies) · 10 intOGen driver records.

Disease family

An umbrella term covering 17 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm

Related subtypes (47): pre-malignant neoplasm, endocrine gland neoplasm, giant cell tumor, hematopoietic and lymphoid system neoplasm, mesenchymal cell neoplasm, epidural spinal canal neoplasm, skeletal muscle neoplasm, trophoblastic neoplasm, cancer, germ cell tumor, benign neoplasm, upper aerodigestive tract neoplasm, histiocytoma, embryonal neoplasm, head and neck neoplasm, epithelial neoplasm, reproductive system neoplasm, non-seminomatous lesion, odontogenic cyst, phosphaturic mesenchymal tumor, thyroglossal duct cyst, hamartoma, mesenchymoma, mesothelial neoplasm, peritoneal neoplasm, virus associated tumor, nail tumor, respiratory tract neoplasm, spindle cell neoplasm, mixed neoplasm, urinary system neoplasm, cystic neoplasm, childhood neoplasm, melanocytic neoplasm, digestive system neoplasm, nervous system neoplasm, neoplasm of thorax, connective tissue neoplasm, bronchial adenomas/carcinoids childhood, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, erythroplakia, retroperitoneal neoplasm, cardiovascular neoplasm, dermoid or epidermoid cyst of the central nervous system, connective and soft tissue neoplasm, NTRK fusion positive cancer, RET fusion positive cancer

Subtypes (17): dermoid cyst of skin, eyelid neoplasm, epidermal appendage tumor, dermis tumor, skin cancer, benign dermal neurilemmoma, actinic keratosis, familial Dupuytren contracture, schwannomatosis, familial multiple discoid fibromas, Maffucci syndrome, hemangiopericytoma of skin, benign neoplasm of skin, melanocytic skin neoplasm, epithelial skin neoplasm, calcifying epithelial odontogenic tumor, familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome

Genetics & variants

GWAS landscape

234 GWAS associations across 46 studies. Top hits map to 26 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1805007	1e-323	MC1R	C	0.38
rs12203592	1e-323	IRF4	C	0.39
rs16891982	1e-181	SLC45A2	C	0.54
rs6059655	5e-173	RALY	A	0.27
rs1126809	6e-138	TYR	G	0.15
rs62211989	4e-85	TPM3P2 - PIGPP3	G	0.25
rs6743068	6e-82	CASP8, FLACC1	A	0.12
rs12350739	2e-65	BNC2 - RN7SL720P	G	0.1
rs12913832	4e-63	HERC2	A	0.12
rs7582362	7e-61	CASP8, FLACC1	A	0.12
rs62244884	2e-57	FOXP1	G	0.09
rs383009	5e-53	CLPTM1L	C	0.09
rs56300457	3e-51	RHOU - LINC02814	T	0.1
rs72928038	5e-47	BACH2	G	0.11
chr2:202165206	1e-46		T	0.1
rs9815073	6e-46	LPP	C	0.11
rs11170164	1e-45	KRT5	C	0.15
rs61824911	3e-45	RHOU - LINC02814	G	0.16
chr10:8944623	1e-42		G	0.12
rs113663016	6e-42	RCC2	G	0.08
chr20:2281970	2e-40		G	0.11
rs11308001	6e-38	IRF4	C	0.13
rs2080303	3e-37	CASP8, FLACC1	C	0.14
rs75507031	2e-36	CASP8, FLACC1	C	0.09
rs7610856	7e-36	FOXP1	C	0.09
rs214793	1e-34	TGM3	T	0.15
rs145102655	2e-34	LINC02676	T	0.19
rs60387933	8e-34	RCC2	A	0.12
chr6:32579277	1e-33		C	0.09
rs117744081	2e-31	CPVL	A	0.2

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475580	Verma A	2024	68,143	360,898	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475585	Verma A	2024	59,327	338,779	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90018921	Sakaue S	2021	25,928	466,275	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90079601	Backman JD	2021	15,858	368,260	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083587	Backman JD	2021	15,858	368,260	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90041830	Jiang L	2021	11,964	444,384	A generalized linear mixed model association tool for biobank-scale data.
GCST90435597	Zhou W	2018	11,149	395,071	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90079596	Backman JD	2021	7,572	380,358	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083582	Backman JD	2021	7,572	380,358	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90043874	Jiang L	2021	6,046	450,302	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	6
Tier 2: splice/UTR	1
Tier 3: regulatory	1
Tier 4: intronic/intergenic	42

MAF distribution

Bucket	Variants
common (>=0.05)	46
low_freq (0.01-0.05)	3
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	31
unknown	7
missense_variant	6
intergenic_variant	4
TF_binding_site_variant	1
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1805007	16	89919709	C>A,G,T	0.082	missense_variant	MC1R	1e-323	Tier 1: coding
rs12203592	6	396321	C>G,T	0.16	intron_variant	IRF4	1e-323	Tier 4: intronic/intergenic
rs16891982	5	33951588	C>A,G	0.038	missense_variant	SLC45A2	1e-181	Tier 1: coding
rs6059655	20	34077942	A>G	0.091	intron_variant	RALY	5e-173	Tier 4: intronic/intergenic
rs1126809	11	89284793	G>A	0.283	missense_variant	TYR	6e-138	Tier 1: coding
rs62211989	20	33950585	G>C	0.058	intergenic_variant	TPM3P2 - PIGPP3	4e-85	Tier 4: intronic/intergenic
rs6743068	2	201289197	A>C,G,T	0.281	intron_variant	CASP8, FLACC1	6e-82	Tier 4: intronic/intergenic
rs12350739	9	16885019	G>A,C,T	0.435	TF_binding_site_variant	BNC2 - RN7SL720P	2e-65	Tier 3: regulatory
rs12913832	15	28120472	A>C,G	0.241	intron_variant	HERC2	4e-63	Tier 4: intronic/intergenic
rs7582362	2	201311571	A>G	0.28	intron_variant	CASP8, FLACC1	7e-61	Tier 4: intronic/intergenic
rs62244884	3	71534232	G>A	0.417	intron_variant	FOXP1	2e-57	Tier 4: intronic/intergenic
rs383009	5	1327736	C>A,G,T	0.412	intron_variant	CLPTM1L	5e-53	Tier 4: intronic/intergenic
rs56300457	1	228848762	T>C,G	0.251	intron_variant	RHOU - LINC02814	3e-51	Tier 4: intronic/intergenic
rs72928038	6	90267049	G>A	0.168	intron_variant	BACH2	5e-47	Tier 4: intronic/intergenic
chr2:202165206				0.282			1e-46	Tier 4: intronic/intergenic
rs9815073	3	188397894	C>A,G	0.324	intron_variant	LPP	6e-46	Tier 4: intronic/intergenic
rs11170164	12	52519884	C>A,G,T	0.077	missense_variant	KRT5	1e-45	Tier 1: coding
rs61824911	1	228843990	A>G	0.05	intron_variant	RHOU - LINC02814	3e-45	Tier 4: intronic/intergenic
chr10:8944623				0.117			1e-42	Tier 4: intronic/intergenic
rs113663016	1	17438131	G>A	0.346	intron_variant	RCC2	6e-42	Tier 4: intronic/intergenic
chr20:2281970				0.203			2e-40	Tier 4: intronic/intergenic
rs11308001	6	392691	CG>C	0.05	intron_variant	IRF4	6e-38	Tier 4: intronic/intergenic
rs2080303	2	201300483	T>A,C,G	0.05	intron_variant	CASP8, FLACC1	3e-37	Tier 4: intronic/intergenic
rs75507031	2	201296039	C>A,T	0.279	intron_variant	CASP8, FLACC1	2e-36	Tier 4: intronic/intergenic
rs7610856	3	71529871	C>A	0.351	intron_variant	FOXP1	7e-36	Tier 4: intronic/intergenic
rs214793	20	2305059	C>G,T	0.05	intron_variant	TGM3	1e-34	Tier 4: intronic/intergenic
rs145102655	10	8897708	TA>T,TAA	0.05	intron_variant	LINC02676	2e-34	Tier 4: intronic/intergenic
rs60387933	1	17426844	C>A,T	0.05	intron_variant	RCC2	8e-34	Tier 4: intronic/intergenic
chr6:32579277				0.422			1e-33	Tier 4: intronic/intergenic
rs117744081	7	29092663	A>G	0.032	missense_variant	CPVL	2e-31	Tier 1: coding

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
128015	NM_005732.4(RAD50):c.2983_2986del (p.Glu995fs)	RAD50	Pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
RAD50	Act	GBM	CIViC #8032

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RAD50	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
RAD50	Orphanet:240760	Nijmegen breakage syndrome-like disorder

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RAD50	HGNC:9816	ENSG00000113522	Q92878	DNA repair protein RAD50	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RAD50	DNA repair protein RAD50	Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RAD50	Other/Unknown	no		Rad50_eukaryotes, Zn_hook_RAD50, P-loop_NTPase

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
calcaneal tendon	1
colonic epithelium	1
corpus callosum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RAD50	134	ubiquitous	marker	corpus callosum, calcaneal tendon, colonic epithelium

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
RAD50	2,552

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
RAD50	Q92878	6

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 21. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Sensing of DNA Double Strand Breaks	1	1903.3×	0.006	RAD50
HDR through MMEJ (alt-NHEJ)	1	878.5×	0.006	RAD50
Impaired BRCA2 binding to PALB2	1	456.8×	0.006	RAD50
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	423.0×	0.006	RAD50
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	423.0×	0.006	RAD50
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	423.0×	0.006	RAD50
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	393.8×	0.006	RAD50
Homologous DNA Pairing and Strand Exchange	1	380.7×	0.006	RAD50
Impaired BRCA2 binding to RAD51	1	308.6×	0.006	RAD50
Resolution of D-loop Structures through Holliday Junction Intermediates	1	300.5×	0.006	RAD50
HDR through Single Strand Annealing (SSA)	1	292.8×	0.006	RAD50
Presynaptic phase of homologous DNA pairing and strand exchange	1	271.9×	0.006	RAD50
HDR through Homologous Recombination (HRR)	1	190.3×	0.008	RAD50
Nonhomologous End-Joining (NHEJ)	1	167.9×	0.008	RAD50
DNA Damage/Telomere Stress Induced Senescence	1	163.1×	0.008	RAD50
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	1	146.4×	0.008	RAD50
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	1	146.4×	0.008	RAD50
Meiotic recombination	1	129.8×	0.009	RAD50
G2/M DNA damage checkpoint	1	120.2×	0.009	RAD50
Regulation of TP53 Activity through Phosphorylation	1	117.7×	0.009	RAD50
Processing of DNA double-strand break ends	1	114.2×	0.009	RAD50

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of mitotic recombination	1	8426.0×	0.001	RAD50
telomeric 3’ overhang formation	1	4213.0×	0.001	RAD50
chromosome organization involved in meiotic cell cycle	1	3370.4×	0.001	RAD50
negative regulation of telomere capping	1	3370.4×	0.001	RAD50
DNA strand resection involved in replication fork processing	1	2106.5×	0.002	RAD50
R-loop processing	1	1685.2×	0.002	RAD50
telomere maintenance via recombination	1	1532.0×	0.002	RAD50
DNA double-strand break processing	1	1532.0×	0.002	RAD50
homologous recombination	1	1404.3×	0.002	RAD50
mitotic G2/M transition checkpoint	1	802.5×	0.002	RAD50
telomere maintenance via telomerase	1	732.7×	0.002	RAD50
reciprocal meiotic recombination	1	561.7×	0.003	RAD50
positive regulation of telomere maintenance	1	510.7×	0.003	RAD50
positive regulation of double-strand break repair	1	343.9×	0.004	RAD50
DNA recombination	1	337.0×	0.004	RAD50
telomere maintenance	1	267.5×	0.005	RAD50
double-strand break repair	1	203.0×	0.006	RAD50
double-strand break repair via homologous recombination	1	156.0×	0.007	RAD50
DNA repair	1	63.8×	0.016	RAD50
DNA damage response	1	53.5×	0.019	RAD50

Therapeutics

Drugs indicated for this disease

6 approved, 13 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Avobenzone	Approved (phase 4)
Dimethicone	Approved (phase 4)
Octinoxate	Approved (phase 4)
Salicylic Acid	Approved (phase 4)
Titanium Dioxide	Approved (phase 4)
Zinc Oxide	Approved (phase 4)
Aldesleukin	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Cyclosporine	Phase 3 (in late-stage trials)
Dacarbazine	Phase 3 (in late-stage trials)
Everolimus	Phase 3 (in late-stage trials)
Interferon Alfa	Phase 3 (in late-stage trials)
Linrodostat	Phase 3 (in late-stage trials)
Nivolumab	Phase 3 (in late-stage trials)
Sirolimus	Phase 3 (in late-stage trials)
Tacrolimus Anhydrous	Phase 3 (in late-stage trials)
Tretinoin	Phase 3 (in late-stage trials)
Vinblastine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Avelumab, Axitinib, Capecitabine, Cemiplimab, Cetuximab, Erlotinib, Fludarabine, Fludarabine Phosphate, Gefitinib, Incomplete Freund’S Adjuvant, Itraconazole, Ornithine, Pembrolizumab, Talabostat, Temozolomide, Veliparib.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
RAD50	1	2

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
MOLIBRESIB	2	RAD50

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
RAD50	7	Binding:7

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

1 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
MOLIBRESIB	2	RAD50

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	RAD50
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 87.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	58
PHASE2	9
PHASE1	6
PHASE1/PHASE2	5
PHASE4	4
PHASE3	2
PHASE2/PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00087490	PHASE4	COMPLETED	Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00129961	PHASE4	COMPLETED	Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
NCT00847912	PHASE4	COMPLETED	CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
NCT05359419	PHASE4	UNKNOWN	Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities
NCT05786716	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT00007631	PHASE3	COMPLETED	Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
NCT00224744	PHASE3	COMPLETED	Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage
NCT06295809	PHASE2/PHASE3	TERMINATED	A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
NCT04305691	PHASE2	RECRUITING	Trial of Ixazomib for Kaposi Sarcoma
NCT07431541	PHASE1/PHASE2	NOT_YET_RECRUITING	Topical Carboxytherapy Paste Following Microneedling
NCT00027586	PHASE2	COMPLETED	Imatinib Mesylate in Treating Patients With Metastatic Melanoma
NCT00094107	PHASE2	COMPLETED	Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
NCT00204789	PHASE2	COMPLETED	Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
NCT00865878	PHASE2	TERMINATED	ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
NCT02303041	PHASE2	TERMINATED	Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
NCT02550678	PHASE1/PHASE2	COMPLETED	A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
NCT02705352	PHASE2	COMPLETED	5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
NCT02836548	PHASE1/PHASE2	COMPLETED	HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
NCT03012581	PHASE2	COMPLETED	Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
NCT03189628	PHASE1/PHASE2	UNKNOWN	The Effect of Autologous Stromal Vascular Fractions on Skin Regeneration
NCT03666325	PHASE2	UNKNOWN	Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance
NCT03887208	PHASE1/PHASE2	COMPLETED	Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells
NCT00698100	PHASE1	COMPLETED	Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines
NCT00993512	PHASE1	COMPLETED	Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
NCT02097875	PHASE1	COMPLETED	Safety Study of a Fluorescent Marker to Visualize Cancer Cells
NCT02145130	PHASE1	COMPLETED	Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects
NCT02602067	PHASE1	TERMINATED	131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
NCT02813902	PHASE1	WITHDRAWN	A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
NCT04630886	EARLY_PHASE1	TERMINATED	Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery
NCT04267861	Not specified	ACTIVE_NOT_RECRUITING	M7824 Related Adverse Effects in Adults With Cancer
NCT05463757	Not specified	RECRUITING	Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
NCT05908435	Not specified	ACTIVE_NOT_RECRUITING	Impact of Sunscreen Dispensers in Parks Visited by Teenagers
NCT07040683	Not specified	RECRUITING	Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: A Multicentre Randomised Study
NCT07062003	Not specified	RECRUITING	Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors, MBRT1 Trial
NCT07188948	Not specified	RECRUITING	In Vivo Cross-Modal Imaging of Skin
NCT07213154	Not specified	RECRUITING	Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions
NCT07298382	Not specified	RECRUITING	See the Impact Beem’s Blue Light Therapy Has on Your Skin Health!
NCT07343544	Not specified	NOT_YET_RECRUITING	Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.
NCT07404605	Not specified	RECRUITING	Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
NCT07415291	Not specified	ACTIVE_NOT_RECRUITING	CNN-Based AI Versus Physicians for Solitary Skin Lesion Diagnosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AMINOLEVULINIC ACID	4	2
SONIDEGIB	4	2
AXITINIB	4	1
BLEOMYCIN	4	1
EFLORNITHINE	4	1
FLUOROURACIL	4	1
IMATINIB	4	1
IXAZOMIB CITRATE	4	1
LINEZOLID	4	1
PERTUZUMAB	4	1
SIROLIMUS	4	1
TRETINOIN	4	1
VANCOMYCIN	4	1
VISMODEGIB	4	1
BUPARLISIB	3	1
TYROSINASE	3	1
FIMAPORFIN	2	1
GUSACITINIB	2	1
INTISMERAN AUTOGENE	2	1
TOZULERISTIDE	2	1
ZENIDOLOL	2	1
CHEMBL4299436	0	1
CHEMBL4854670	0	1
CHEMBL3939307	0	1
CHEMBL1813256	0	1
ALMOND OIL	-1	1